Innate Pharma (IPHA) Operating Income (2020 - 2025)

Innate Pharma has reported Operating Income for 5 years, with the latest figure at -$28.8 million in Q2 2025.

• For the quarter ending Q2 2025, Operating Income fell 1.57% year-over-year to -$28.8 million; the trailing twelve-month figure through Jun 2025 stood at -$112.3 million (down 47.8% YoY), and the FY2025 full-year result was -$62.9 million, down 14.07% from the prior year.
• Operating Income for Q2 2025 stood at -$28.8 million, down from -$28.3 million in the prior quarter.
• The five-year high for Operating Income was $7.5 million in Q2 2021, with the low at -$54.7 million in Q4 2021.
• Historically, Operating Income has averaged -$20.9 million across 4 years, with a median of -$28.3 million in 2024.
• Annual changes were most pronounced in 2021 — Operating Income jumped 181.84% — and 2024, when it tumbled 6438.23%.
• Innate Pharma's Operating Income stood at -$54.7 million in 2021, then soared by 99.21% to -$433391.9 in 2023, then plunged by 6438.23% to -$28.3 million in 2024, then retreated by 1.57% to -$28.8 million in 2025.
• The last three Operating Income figures came in at -$28.8 million (Q2 2025), -$28.3 million (Q2 2024), and -$433391.9 (Q2 2023), per Business Quant data.